Literature DB >> 449947

Mineralocorticoid-induced hypertension in patients with orthostatic hypotension.

A V Chobanian, L Volicer, C P Tifft, H Gavras, C S Liang, D Faxon.   

Abstract

The mechanism of recumbent hypertension induced by fludrocortisone was studied in seven patients with orthostatic hypotension. All showed increases in blood pressure in the recumbent and standing positions, and hypertensive levels were achieved on recumbency in four of them. Hypertensive retinopathy developed in two patients and cardiomegaly in one. Initial blood-pressure elevations were associated with sodium retention and plasma-volume expansion. However, with long-term treatment, plasma volume decreased to control levels despite further blood-pressure increases. Treatment did not affect plasma levels of catecholamines but did enhance pressor responsiveness to infused norepinephrine in some subjects. Hemodynamic studies indicated that hypertension in the recumbent position was related to increases in total peripheral-vascular resistance and not to changes in cardiac output. Clinically, hypertension in the recumbent position is an important risk of fludrocortisone treatment in patients with orthostatic hypotension. This unusual model of chronic mineralocorticoid-induced hypertension is not volume dependent but is related to increased peripheral-vascular resistance.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 449947     DOI: 10.1056/NEJM197907123010202

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  52 in total

Review 1.  New trends in the treatment of orthostatic hypotension.

Authors:  J Jordan
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

2.  Epidemiology, Diagnosis, and Management of Neurogenic Orthostatic Hypotension.

Authors:  Jose-Alberto Palma; Horacio Kaufmann
Journal:  Mov Disord Clin Pract       Date:  2017-03-16

Review 3.  Management of neurogenic orthostatic hypotension in patients with autonomic failure.

Authors:  Christoph Schroeder; Jens Jordan; Horacio Kaufmann
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

4.  Orthostatic hypotension in older persons: a diagnostic algorithm.

Authors:  T Krecinic; F Mattace-Raso; N Van Der Velde; G Pereira; T Van Der Cammen
Journal:  J Nutr Health Aging       Date:  2009-06       Impact factor: 4.075

5.  Midodrine for TCA-induced orthostatic hypotension.

Authors:  D D Maskall; R W Lam
Journal:  J Psychiatry Neurosci       Date:  1993-11       Impact factor: 6.186

Review 6.  Management of Supine Hypertension Complicating Neurogenic Orthostatic Hypotension.

Authors:  Jacquie Baker; Kurt Kimpinski
Journal:  CNS Drugs       Date:  2017-08       Impact factor: 5.749

7.  Fludrocortisone in the treatment of hypotensive disorders in the elderly.

Authors:  R M Hussain; S J McIntosh; J Lawson; R A Kenny
Journal:  Heart       Date:  1996-12       Impact factor: 5.994

Review 8.  Drug-induced hypertension. Recognition and management in older patients.

Authors:  P W de Leeuw
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

9.  Benefits of fludrocortisone in the treatment of symptomatic vasodepressor carotid sinus syndrome.

Authors:  D da Costa; S McIntosh; R A Kenny
Journal:  Br Heart J       Date:  1993-04

10.  Clinical characteristics of supine hypertension in de novo Parkinson disease.

Authors:  Tadashi Umehara; Hiromasa Matsuno; Chizuko Toyoda; Hisayoshi Oka
Journal:  Clin Auton Res       Date:  2015-11-27       Impact factor: 4.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.